| Metric | Q3'25 | Q4'25 | Change |
|---|---|---|---|
| Revenue | $39.9M Q3 (+222% YoY) | $61.9M Q4 (+429% YoY) | Q/Q acceleration to +55% above own guidance |
| Full Year Revenue | $37.5M FY2024 | $130M FY2025 (+202% YoY) | First quantum company past $100M |
| Adjusted EBITDA Q4 | -$48.9M Q3 | -$67.4M Q4 | Loss widened 38% despite revenue surge |
| Full Year Adj EBITDA | Guided -$206M to -$216M | -$186.8M actual | Beat own EBITDA guidance by $19-30M |
| R&D Spending Q4 | $66.3M Q3 | $96.1M Q4 | 45% quarter-over-quarter surge |
| Full Year R&D | $137M FY2024 | $305.7M FY2025 | 123% increase, now 2.4x of revenue |
| Cash Balance | $1.5B Q3 | $3.3B Q4 | Added $1.8B from equity raise |
| Remaining Performance Obligations | $77M end-2024 | $370M end-2025 | Nearly 5x backlog growth |
| Stock-Based Compensation | $72.9M Q3 | Not disclosed Q4 | Stopped breaking out SBC in Q4 |
| International Revenue Mix | ~30% Q3 | >30% FY2025 | First time above 30% annually |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.